New-onset refractory status epilepticus as an early manifestation of multisystem inflammatory syndrome in adults after COVID-19

Epilepsia. 2022 May;63(5):e51-e56. doi: 10.1111/epi.17231. Epub 2022 Mar 27.

Abstract

Multisystem inflammatory syndrome in adults (MIS-A) is a rare hyperinflammatory complication with multi-organ involvement that manifests a few weeks after recovering from a typically mild coronavirus disease 2019 (COVID-19) infection. Although encephalopathy and seizures can occur in the acute phase of COVID-19, the nervous system is infrequently involved in patients with MIS-A. Herein, we describe the case of a young woman who presented with new-onset refractory status epilepticus (NORSE) following a mild COVID-19 infection associated with symptoms, signs, and laboratory findings that satisfy the updated Centers for Disease Control and Prevention (CDC) definition of MIS-A. Magnetic resonance imaging of the brain revealed symmetric T2-signal increase involving both orbitofrontal lobes, insulae, and hippocampi. One of the notable findings in our patient was the quick response and significant clinical recovery that occurred following initiation of treatment with intravenous methylprednisolone and intravenous immunoglobulin. Our case expands the clinical spectrum of MIS-A and documents the occurrence of NORSE as one of its early clinical manifestations. A routine comprehensive clinical and laboratory assessment is needed to screen for this underdiagnosed condition, especially in patients with post-COVID-19 inflammatory complications.

Keywords: Covid-19; IVIG; Multisystem inflammatory syndrome; NORSE; SARS-CoV-2; Status epilepticus.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adult
  • COVID-19* / complications
  • Female
  • Humans
  • SARS-CoV-2
  • Status Epilepticus* / drug therapy
  • Status Epilepticus* / etiology
  • Systemic Inflammatory Response Syndrome / complications

Supplementary concepts

  • adult multisystem inflammatory disease, COVID-19 related